Technologies

With the EnteriCare® patented† technology, the enteric properties are integrated into the gelatin shell, not a coating. The result is an elegant, clear capsule that targets delivery to the small intestine, reducing risks of reflux, gastric irritation, and transformation of acid-labile compounds. EnteriCare enteric softgels allow for the delayed release of your compound with the clear-dosage form consumers prefer.1

VersatrolTM from Banner Life Sciences is an innovative patent-pending technology that can provide controlled release for a wide range of pharmaceuticals by incorporating the active ingredient in a lipophilic or hydrophilic matrix that is then incorporated into a soft-gelatin shell. Depending on the physicochemical properties of the drug, either a suspension or emulsion formulation can be developed. For lipophilic drugs a suspension formulation is utilized, while for hydrophilic drugs an emulsion formulation is preferred. Importantly, by applying varying combinations of hydrophilic and lipophilic excipients, customized-release profiles can be achieved.2

Chewels®, a patented† technology, is an adaptable platform that can be formulated to provide desired sensory characteristics. Combined with significant load capacity, Chewels offers a broad range of formulation capabilities. Our laboratory-dissolution tests indicate that the drug release from Chewels formulation can be tailored to match the release that of standard commercial tablets.4

The LiquiSoftTM patented‡ technology is the solid-dosage solution for when your molecule requires an oral liquid formulation. This unique chewable liquid-filled softgel is convenient, pleasant tasting, and appealing.